1. Home
  2. LIXT vs PURR Comparison

LIXT vs PURR Comparison

Compare LIXT & PURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$3.33

Market Cap

25.4M

Sector

Health Care

ML Signal

HOLD

PURR

Hyperliquid Strategies Inc

N/A

Current Price

$4.36

Market Cap

24.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LIXT
PURR
Founded
2005
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.4M
24.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LIXT
PURR
Price
$3.33
$4.36
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$6.58
AVG Volume (30 Days)
84.6K
1.5M
Earning Date
11-12-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$3.01
52 Week High
$6.26
$4.65

Technical Indicators

Market Signals
Indicator
LIXT
PURR
Relative Strength Index (RSI) 42.48 67.10
Support Level $3.04 $3.26
Resistance Level $3.53 $3.90
Average True Range (ATR) 0.33 0.33
MACD 0.01 0.06
Stochastic Oscillator 43.92 83.09

Price Performance

Historical Comparison
LIXT
PURR

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: